This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yu, D. Articles by Brunzell, J. D Search for Related Content PubMed PubMed Citation Articles by Yu, D. Articles by Brunzell, J. D Social Bookmarking                         What's this?

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

GlaxoSmithKline, 2301 Renaissance Boulevard, Building 510, King of Prussia, PA 19406, US

Susan J Murdoch

University of Washington, Seattle, WA, US

Shamik J Parikh

GlaxoSmithKline, 2301 Renaissance Boulevard, Building 510, King of Prussia, PA 19406, US

Santica M Marcovina

University of Washington, Seattle, WA, US

Alexander Cobitz

GlaxoSmithKline, 2301 Renaissance Boulevard, Building 510, King of Prussia, PA 19406, US

Hongzi Chen

GlaxoSmithKline, 2301 Renaissance Boulevard, Building 510, King of Prussia, PA 19406, US

John D Brunzell

University of Washington, Seattle, WA, US

A substantial number of individuals with type 2 diabetes mellitus (T2DM) demonstrate a predominance of small dense low-density lipoprotein (sdLDL), which is associated with an increased risk of cardiovascular disease (CVD). In some cases, sdLDL persists after treatment with a statin to reduce levels of LDL. The effect of the addition of a thiazolidinedione, rosiglitazone (RSG) (4 mg/day or 8 mg/day) to statin therapy on LDL phenotype and C reactive protein (CRP) levels was investigated in a 12-week, placebo-controlled study of 72 T2DM patients who were well controlled and on a statin, but who had persistently predominant sdLDL.

Addition of RSG 8 mg to statin therapy significantly increased LDL buoyancy (relative flotation +0.014, p=0.003) and LDL particle size (+4.2Å, p=0.001) from baseline and relative to the change with placebo (+0.014 and +3.8Å; p=0.03 and p=0.04, respectively), and was associated with a non-significant decrease in sdLDL. RSG 8 mg moderately, but significantly, increased total cholesterol (by 12.2%, p=0.004), LDL-cholesterol (11.2%, p=0.02) and intermediate-density lipoprotein (IDL)-cholesterol from baseline but did not increase total or LDL apolipoprotein B. RSG 4 mg and 8 mg significantly reduced CRP compared with placebo (-44.9% and-48.0%; p=0.008 and p=0.004, respectively), and significantly reduced insulin resistance and fasting plasma glucose from baseline.

Addition of RSG to statin therapy may further reduce cardiovascular risk by improving the LDL phenotype, as well as reducing insulin resistance and CRP levels. However, the increase in IDL may be proatherogenic and must be considered when assessing the benefits of rosiglitazone.

Key Words: C-reactive protein • rosiglitazone • small dense low-density lipoprotein phenotype • statin • thiazolidinediones • type 2 diabetes mellitus.

Diabetes and Vascular Disease Research, Vol. 3, No. 3, 189-196 (2006)
DOI: 10.3132/dvdr.2006.029


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?